HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2- (methoxycarbonyl(4- methoxyphenyl)methylsulfanyl)- 1H- benzimidazole- 4- carboxylic acid amide

putative cardioprotective agent; structure in first source

Also Known As:

KR 33889; KR-33889; KR33889

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzimidazoles: 245
      - 2-(methoxycarbonyl(4-methoxyphenyl)methylsulfanyl)-1H-benzimidazole-4-carboxylic acid amide: 2
Organic Chemicals: 133
- Carboxylic Acids: 973
  - Carbocyclic Acids
    - Phenylacetates: 3
      - 2-(methoxycarbonyl(4-methoxyphenyl)methylsulfanyl)-1H-benzimidazole-4-carboxylic acid amide: 2

Experts

1.	Yi, Kyu Yang: 2 articles (05/2017 - 01/2009)
2.	Chung, Hun-Jong: 1 article (05/2017)
3.	Jang, Yong Chang: 1 article (05/2017)
4.	Kang, Do-Hyun: 1 article (05/2017)
5.	Kang, Jun Chul: 1 article (05/2017)
6.	Kim, Bokyung: 1 article (05/2017)
7.	Kim, Dae-Eun: 1 article (05/2017)
8.	Lee, Min-Ju: 1 article (05/2017)
9.	Park, Eun-Seok: 1 article (05/2017)
10.	Shin, Hwa-Sup: 1 article (05/2017)

Related Diseases

1.	Myocardial Ischemia (Ischemic Heart Diseases) 05/01/2017 - "Taken together, these results suggest that KR-33889 may have therapeutic potential to prevent I/R-induced heart injury in ischemic heart diseases mainly by reducing oxidative stress-mediated myocardial apoptosis." 01/01/2009 - "These results indicate that the novel PARP inhibitor KR-33889 exerts its cardioprotective effect in in vitro and in vivo studies of myocardial ischemia via potent PARP inhibition and also suggest that KR-33889 could be an attractive therapeutic candidate with oral activity for several cardiovascular disorders, including myocardial infarction."
2.	Myocardial Infarction 01/01/2009 - "In separate experiments for the therapeutic time window study, KR-33889 (3 mg/kg i.v.) given at preischemia, at reperfusion or in both, in rat models also significantly reduced the myocardial infarction compared with their respective vehicle-treated group. " 01/01/2009 - "In anesthetized rats subjected to 30 min of coronary occlusion and 3 h of reperfusion, KR-33889 (0.3-3 mg/kg i.v.) dose-dependently reduced myocardial infarct size. " 01/01/2009 - "These results indicate that the novel PARP inhibitor KR-33889 exerts its cardioprotective effect in in vitro and in vivo studies of myocardial ischemia via potent PARP inhibition and also suggest that KR-33889 could be an attractive therapeutic candidate with oral activity for several cardiovascular disorders, including myocardial infarction."
3.	Coronary Occlusion 01/01/2009 - "In anesthetized rats subjected to 30 min of coronary occlusion and 3 h of reperfusion, KR-33889 (0.3-3 mg/kg i.v.) dose-dependently reduced myocardial infarct size. "
4.	Ischemia 01/01/2009 - "A novel and orally active poly(ADP-ribose) polymerase inhibitor, KR-33889 [2-[methoxycarbonyl(4-methoxyphenyl) methylsulfanyl]-1H-benzimidazole-4-carboxylic acid amide], attenuates injury in in vitro model of cell death and in vivo model of cardiac ischemia."
5.	Heart Injuries 05/01/2017 - "Taken together, these results suggest that KR-33889 may have therapeutic potential to prevent I/R-induced heart injury in ischemic heart diseases mainly by reducing oxidative stress-mediated myocardial apoptosis."

Related Drugs and Biologics

1.	Poly(ADP-ribose) Polymerase Inhibitors
2.	Carboxylic Acids
3.	Amides
4.	benzimidazole